Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The artificial pancreas device system (APDS) industry is going through a transition that is showing a definite trend towards the control of diabetes. Another important development is the growing preference for intergrating CGM systems with insulin delivery systems in APDS or automated personalized diabetes systems. It enables the instant diagnosis of blood glucose and an adjustment of the insulin pump at the same time. The affected people are given an extremely automated method of glycemic control. This tendency fits to the common pattern of the personalized technology-driven diabetes management, where people are equipped with a more polished and automated-adjustable tool to impove blood glucose levels and relieve from the device of feeling stress and make processes slower.
In addition to the above, the second important aspect is the creation of closed-loop system that will be powered with hybrids. These systems offer the benefits that come with a combination of open-loop and closed-loop systems; they give users the best of both worlds by providing both flexibility and control over their insulin dosage while simultaneously taking advantage of the automation feature to maintain the glucose level within the optimal range. This is a sign of a strategic approach to diabetes management that takes into account the involvement of users with personalization, in addition to the benefits of automation.
Consequently, the APDS customer base has also got benefited tremendously and it is experiencing upgrades in algorithms. The move of APDS algorithms to be smarter is accelerating now and these means deploying machine learning and Artificial Intelligence to analyze complicated data profiles and then predict individualized insulin doses. Besides, such tendency to adjust and react to the ongoing variations of glucose metabolism and user demands strengthens the level of the efficiency of APDS at its operation.
Moreover, there has been a growing trend to build interoperability into the system which is crucial for the function of diabetes management solutions along with healthcare systems as one unit. Implementation leads to data sharing between devices and therefore forms a collaborative and widespread basis for diabetes care. This tendency coincides with the call for seamless health networks and patient-centered management system, which facilitate communication between the teams and services involved with diabetes care.
The APDS lends new discoveries here too, as the targeting toward pediatrician populations begins. Through the course of time and years as these systems are established and their safety and efficacy is accepted, the importance of APDS in the treatment of diabetes in children and adolescents is clearly seen. This testifies to the determination to target particular problems and use of modern tools that gives children and relatives the ability to handle the glycemic control in children well.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Market Opportunities | Product Manufacturer |
Artificial Pancreas Device System Market Highlights:
Global Artificial Pancreas Device System Market Overview
The Artificial Pancreas Device System Market size is anticipated to reach USD 0.4 billion by 2032 at 17% CAGR during the forecast period 2023-2032.The need for artificial pancreas devices has recently surged as the number of instances involving pancreatic diseases and malfunctions has climbed significantly. The increasing number of diabetes patients detected is a crucial driver in encouraging market expansion.
Artificial Pancreas Device System Market Trends
The increased infusion of investment into the industry is predicted to improve product quality, hence increasing market sales. Patients are more involved in the selection of their treatment alternatives in some circumstances now that they are more or less aware of the treatment possibilities. This aspect is expected to favorably impact the growth of the market over the forecast period.
The market perspective offered by MRFR spans the entire market and gives in-depth coverage of the latest trends that are shaping the future of the artificial pancreas device system industry. The report aptly captures the development of the market through current market trends, historical growth analysis, and revenue projections for a period ranging to 2023. The market also mentions CTR (Control to Range) Systems and CTT (Control to Target) Systems. The end user segments such as hospital and medical centers are also significantly emphasized upon, and a detailed analysis of the segments is also presented in the report. The market dynamics related to pricing and feasibility analysis is significantly along with macroeconomic indicators, and feasibility indicators provides a comprehensive overview of the artificial pancreas device system market in the forecast period.
The report on the artificial pancreas device system consists of market dynamics, forecast, historical market trends, market value by region as well as by country-level analysis for each market segment, segmentation, market factor analysis and key player’s market share analysis that includes supply chain and Porter’s five forces analysis of the market.
Artificial Pancreas Device System Industry Developments
In october 2023,
Medtronic received FDA approval for their MiniMed 780G system, a hybrid closed-loop system with features like automated basal rate adjustments and mealtime bolusing suggestions.
In November 2023,
Dexcom received FDA approval for their G7 continuous glucose monitoring (CGM) system, featuring a smaller sensor and improved accuracy.
Bigfoot Biomedical is a medical device business that is revolutionizing diabetes care for patients who require insulin. The business is working on an end-to-end type 1 diabetes management system that employs a simple design, cloud connection, and human-centered automation. It improves insulin administration and delivery via an integrated medical device ecosystem powered by machine learning and augmented by secure, user-friendly consumer technology, radically altering the care paradigm.
Tandem Diabetes Care Inc (Tandem) is a medical device manufacturer that creates diabetes care devices. The t: slim X2 insulin pump, basal-IQ technology, Control-IQ technology, software and apps, infusion sets, and various pump accessories are all part of the company's product line. It also provides linked health services. It also offers product support services to assist its customers in further customizing their systems. The firm sells its products in almost all the countries such as Australia, New Zealand, South Africa, France, and Germany. Tandem's headquarters are in San Diego, California, USA.
Key Companies in the market of artificial pancreas device system include
- Medtronic Plc
- Bigfoot Biomedical
- Johnson & Johnson
- Dexcom Inc.
- Cellnovo
- Pancreum Inc.
- TypeZero Technologies LLC
- Beta Bionics
- F. Hoffmann-La Roche Ltd
- Tandem Diabetes Care Inc.
- Inreda Diabetic B.V.
- Insulet Corp
Artificial Pancreas Device System Market Segmentation
The segmentation of the artificial pancreas device market has been carried out to better gauge the market.
Artificial Pancreas Device System Type Outlook
- CTR (Control to Range) Systems
- CTT (Control To Target) Systems
Artificial Pancreas Device System End User Outlook
- Hospitals
- Medical Centers
Artificial Pancreas Device System Region Outlook
- North America
- South America
- Europe
- Asia-Pacific
- Middle East
- Africa
Research Methodology
The progression of research while creating reports at Market Research Future includes highlights and facts that are essential to the expansion of artificial pancreas device system. The research initiated by our analysts enhances the capability of our clients to outline their vision for growth better. The unification of primary and secondary research approaches in our reports divulges widespread information connected to new revenue pockets and developing markets globally. The report methodology also ensures strategy roadmaps that exhibit a distinct picture of the present trends as well as the trends that can affect the forthcoming development of the artificial pancreas device system industry. An intrinsic level of understanding connected to the value chain in a specific market additionally contributes to the value of the reports created by our analysts. Furthermore, the insights into markets, technologies, and industry sectors is positively achieved by the application of top-down and bottom-up approaches.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
